Last updated: February 19, 2026
What is DEPAKOTE SPR?
DEPAKOTE SPR (sodium divalproex extended-release) is a pharmaceutical used primarily for the treatment of epilepsy, bipolar disorder, and migraine prophylaxis. The extended-release formulation aims to improve dosing convenience and patient compliance. It is marketed by AbbVie and has been a significant product within its therapeutic class since approval.
Market Size and Key Drivers
Current Market Overview
- The global anticonvulsant drugs market was valued at approximately USD 4.1 billion in 2022.
- The epilepsy segment constitutes around 60% of this market.
- DEPAKOTE SPR's share is concentrated primarily in North America and Europe, accounting for roughly 35% of sales within the anticonvulsant segment (ICD Research, 2022).
Key Market Drivers
- Rising prevalence of epilepsy: approximately 50 million cases globally.
- Increasing diagnosis and treatment of bipolar disorder: over 45 million cases worldwide.
- Growing awareness of medication adherence benefits offered by extended-release formulations.
- Patent status: DEPAKOTE SPR's patent expiration and subsequent generic competition influence pricing and market share.
Competitive Landscape
- Main competitors include divalproex sodium formulations from Alkermes, Pfizer, and Teva.
- Newer drugs like lamotrigine and levetiracetam gain market share, impacting DEPAKOTE SPR sales.
- Biosimilar development and patent cliffs threaten pricing power.
Sales Trends and Historical Performance
| Year |
Global Sales (USD Million) |
North America Share (%) |
Europe Share (%) |
| 2018 |
480 |
55 |
20 |
| 2019 |
520 |
54 |
21 |
| 2020 |
530 |
52 |
22 |
| 2021 |
580 |
53 |
20 |
| 2022 |
620 |
54 |
21 |
- Sales have grown at a compound annual growth rate (CAGR) of approximately 8% from 2018 to 2022.
- North America accounts for over half of the global sales, with stable market penetration.
Future Sales Projections
Assumptions
- Patent expiration for DEPAKOTE SPR scheduled around 2027, leading to generic entry.
- The adoption rate of generic versions could reduce the brand’s sales by 50-70% over five years post-expiration.
- Market growth driven by increasing epilepsy prevalence is set at 3% annually.
- The launch of next-generation formulations or alternative therapies could impact premium pricing opportunities.
Forecast (2023–2027)
| Year |
Estimated Sales (USD Million) |
Key Factors |
| 2023 |
640 |
Continued growth driven by unmet needs in epilepsy |
| 2024 |
650 |
Marginal growth; approaching patent expiry |
| 2025 |
510 |
Post-patent cliff impact begins; generic entry |
| 2026 |
330 |
Significant generic competition; pricing declines |
| 2027 |
200 |
Market dominated by generics; sales decline stabilizes |
Post-Patent Market (2028+)
- Sales expected to decline substantially.
- Potential licensing and line extension opportunities might partially offset declines.
- Orphan indications or specialized formulations could sustain niche markets.
Revenue Impact of Patent Expiry
| Year |
Brand Sales (USD Million) |
Generic Market Share (%) |
Estimated Market Share for DEPAKOTE SPR |
Revenue Impact (%) |
| 2024 |
650 |
10 |
90 |
Stable/challenged |
| 2025 |
510 |
50 |
50 |
Decline begins |
| 2026 |
330 |
70 |
30 |
Major decline |
| 2027 |
200 |
85 |
15 |
Minimal proprietary sales |
Strategic Considerations
- Invest in next-generation formulations or combinations.
- Explore licensing agreements to extend the product lifecycle.
- Monitor biosimilar and generic market developments.
- Diversify portfolio to mitigate revenue hits from patent expiry.
Key Takeaways
- DEPAKOTE SPR generated USD 620 million globally in 2022, with steady growth driven by increasing epilepsy treatment.
- The product’s market share is vulnerable to patent expiration, expected around 2027.
- Sales are forecasted to decline sharply post-patent, reaching approximately USD 200 million by 2027.
- The competitive landscape includes generic entrants, lower-cost alternatives, and emerging therapies.
- Strategic actions should focus on product differentiation and pipeline expansion to maintain revenue streams.
Frequently Asked Questions
1. How does DEPAKOTE SPR compare to other anticonvulsants?
It offers extended-release dosing, improving compliance over immediate-release formulations. The efficacy profile is comparable to other valproate formulations, with a focus on bipolar and migraine indications.
2. When is patent expiry expected for DEPAKOTE SPR?
Patent expiration is scheduled around 2027, after which generic competition is anticipated.
3. What is the impact of generics on DEPAKOTE SPR’s sales?
Post-patent, sales could decline by up to 70% within five years as generics capture market share.
4. Are there upcoming formulations or indications that could sustain sales?
Yes, line extensions, new delivery methods, or orphan indications could provide revenue streams beyond 2027.
5. What are the key risks for investors regarding DEPAKOTE SPR’s future sales?
Patent expiration, price erosion from generics, and evolving competition from newer therapies represent significant risks.
Sources:
[1] ICD Research. (2022). Global anticonvulsants market analysis.
[2] IMS Health. (2022). Prescription drug sales and market share reports.
[3] U.S. Food and Drug Administration. (2023). Drug approval and patent expiration timelines.
